See other bills
under the
same topic
PRINTER'S NO. 2768
THE GENERAL ASSEMBLY OF PENNSYLVANIA
HOUSE RESOLUTION
No.
588
Session of
2019
INTRODUCED BY READSHAW, MEHAFFIE, HARKINS, MOUL, HILL-EVANS,
CALTAGIRONE AND DeLUCA, OCTOBER 23, 2019
REFERRED TO COMMITTEE ON HEALTH, OCTOBER 23, 2019
A RESOLUTION
Recognizing Fathom Pharma LLC for its efforts to mitigate the
opioid crisis and expressing support for continued innovation
by the pharmaceutical industry.
WHEREAS, Injuries and deaths attributable to the use of
prescription opioids and illicit opioids have reached epidemic
proportions in this Commonwealth and across the United States;
and
WHEREAS, In 2018, an estimated 4,491 drug overdose deaths
from accidental or undetermined causes were recorded in
Pennsylvania; and
WHEREAS, The Centers for Disease Control and Prevention
states that "opioid addiction is a major driver of drug
diversion"; and
WHEREAS, Prescription opioids are more likely to be diverted
or misused than other prescription medications; and
WHEREAS, Misuse of prescription opioids occurs among 21% to
29% of patients with chronic pain; and
WHEREAS, Fathom Pharma LLC is a biotechnology company
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
dedicated to treating pain and combating the opioid epidemic;
and
WHEREAS, Fathom Pharma's main laboratory is located in
Hummelstown; and
WHEREAS, Fathom Pharma is developing a long-acting injectable
pain relief (LAIPR) medication with an opioid reformulation that
provides continuous pain relief for 3 to 14 days among surgery
patients and 30 to 90 days among patients with chronic pain; and
WHEREAS, LAIPR may combat the opioid epidemic by reducing
potential misuse or abuse among patients and reducing risks to
others by taking pills off the streets and preventing them from
being lost, stolen or given away; and
WHEREAS, LAIPR may relieve prescription opioid dependence and
withdrawal by providing consistent levels of medication over an
established time frame within the therapeutic window; and
WHEREAS, Fathom Pharma is ready to begin the approval process
for clinical trials, which are likely to take place in our
Commonwealth; therefore be it
RESOLVED, That the House of Representatives recognize Fathom
Pharma LLC for its efforts to mitigate the opioid crisis; and be
it further
RESOLVED, That the House of Representatives express support
for Fathom Pharma LLC and other innovative pharmaceutical
companies involved in developing pain medications that are
effective treatments while being difficult to divert or misuse.
20190HR0588PN2768 - 2 -
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25